The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Paper in leading Journal

30 Nov 2018 07:00

RNS Number : 9782I
DeepMatter Group PLC
30 November 2018
 

30 November 2018

DeepMatter Group plc

("DeepMatter", or the "Group")

 

Publication of Paper in Science

 

DeepMatter, the AIM-listed company focusing on digitizing chemistry, announces that its founding scientific director, Professor Lee Cronin, and his colleagues at the University of Glasgow have today published a paper in Science, a leading international journal. DeepMatter has rights to intellectual property arising from the laboratory of Professor Cronin as part of its Intellectual Property and Royalty agreement with the University of Glasgow.

 

The paper describes for the first time a method of molecule production which uses downloadable 'blueprints' to easily and reliably synthesise chemicals, such as drug molecules, automatically via a programmable chemical-robot: a 'Chemputer'. The idea of the 'Chemputer' is underpinned by a universal and interoperable standard for writing and sharing chemical recipes, developed by the University of Glasgow team. A number of the scientific concepts detailed in this paper make up a critical part of DeepMatter's commercial strategy.

 

DeepMatter has used its own universal and interoperable standard for writing and sharing chemical recipes as part of its DigitalGlassware™ platform. Currently, the platform allows experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. It is designed to enable scientists to work together effectively, sharing the details of their experiments in real time from anywhere so that work is not needlessly duplicated, time and money wasted, and ultimately so that new discoveries may be made faster.

 

DeepMatter's long term goal is to use DigitalGlassware™ to control robotics and to ultimately progress towards a commercially viable Chemputer™. In 2017, as part of its strategy to build its commercial market presence for the digitization of chemistry, DeepMatter registered the trademark for the Chemputer™ brand.

 

The full scientific Paper, 'Organic synthesis in a modular robotic system driven by a chemical programming language' can be found at www.sciencemag.org

 

Mark Warne, CEO of DeepMatter, commented:

 

"We are very pleased to see the work of our founding scientific director published in Science today. The recognition of such an esteemed publication demonstrates the significance of both the University of Glasgow's important research and our work here at DeepMatter, translating these advances into a commercially viable strategy.

 

"We believe that these developments can truly disrupt the way in which process and discovery chemistry is carried out today, bringing huge financial benefits to those working in these industries. We are very pleased to have the first stage of the DigitalGlasswareTM launch underway and look forward to continuing to educate chemists worldwide as to the benefits of using the platform."

 

For further information:

 

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Stockdale Securities Limited

 

T: 020 7601 6100

Tom Griffiths

Edward Thomas

 

 

 

Alma PR

Caroline Forde

Rebecca Sanders-Hewett

Susie Hudson

 

T: 020 3405 0209

deepmatter@almapr.co.uk

 

About DeepMatter:

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

More information is available here: http://www.deepmattergroup.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAPFNAELPFFF
Date   Source Headline
13th Apr 20167:00 amRNSPreliminary Results
21st Oct 20157:00 amRNSCompletion of Capital Reorganisation
7th Oct 20151:56 pmRNSResult of Court Hearing
29th Sep 20153:33 pmRNSHolding(s) in Company
28th Sep 201510:02 amRNSHolding(s) in Company
16th Sep 20157:00 amRNSChange of Name
15th Sep 20153:32 pmRNSHolding(s) in Company
15th Sep 201510:02 amRNSDirectors' Interest in Shares
15th Sep 201510:01 amRNSDirectorate Changes
15th Sep 201510:00 amRNSCompletion of Placing and Acquisition
11th Sep 201510:00 amRNSApplication for Admission
10th Sep 201511:16 amRNSResult of General Meeting
25th Aug 20155:10 pmRNSHalf Yearly Report
25th Aug 20155:05 pmRNSAcquisition and related matters
7th Jul 20157:00 amRNSChange of Name
30th Jun 201512:10 pmRNSResult of AGM
4th Jun 20158:35 amRNSReplacement: Final Results
4th Jun 20157:00 amRNSDirectorate Change
4th Jun 20157:00 amRNSFinal Results
8th Jan 20155:56 pmRNSHolding(s) in Company
9th Sep 20147:00 amRNSCompletion of investment in subsidiary
29th Aug 20147:00 amRNSHalf Yearly Report
14th Jul 201411:00 amRNSResult of AGM
30th Jun 20147:00 amRNSFirst commercial sale
17th Jun 20147:00 amRNSFinal Results
17th Mar 20147:00 amRNSGraphene Functionalisation Capabilities
3rd Feb 20147:00 amRNSProject Announcement
24th Jan 20147:00 amRNSOAS launches OntoTM Development Pack for customer
18th Nov 20135:43 pmRNSHolding(s) in Company
30th Oct 20137:00 amRNSDirectorate Change
18th Oct 20137:00 amRNSChange to substantial shareholdings
20th Sep 20137:00 amRNSDirectorate Change
28th Aug 20139:40 amRNSHalf Yearly Report
13th Jun 20135:30 pmRNSAGM Statement
1st May 20137:00 amRNSFinal Results
12th Apr 20131:10 pmRNSHolding(s) in Company
13th Mar 20138:42 amRNSHolding(s) in Company
12th Mar 20138:37 amRNSHolding(s) in Company
6th Mar 20134:03 pmRNSHolding(s) in Company
9th Jan 20137:00 amRNSTechnical Advisory Board Enhanced
7th Jan 20134:25 pmRNSHolding(s) in Company
20th Dec 20121:55 pmRNSHolding(s) in Company
5th Dec 20125:33 pmRNSHolding(s) in Company
12th Nov 20128:51 amRNSHolding(s) in Company
3rd Oct 20127:00 amRNSDirectors' Interest in Shares
26th Sep 20127:00 amRNSInterim Statement
24th Sep 20129:58 amRNSHolding(s) in Company
17th Sep 20129:26 amRNSHolding(s) in Company
1st Aug 20127:00 amRNSAppointment of CEO
15th Jun 201212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.